New Daily Pill Orforglipron Shows Promise in Maintaining Weight Loss Post-Injections
A recent trial has revealed that a daily pill, orforglipron, could help individuals maintain weight loss after discontinuing injectable medications like tirzepatide and semaglutide. Conducted by researchers and funded by Eli Lilly, the trial involved 376 U.S. patients who had been on these injections for 72 weeks. Participants who switched to orforglipron managed to retain a significant portion of their weight loss compared to those on a placebo. Specifically, those who had been on tirzepatide maintained nearly 75% of their weight loss, while those on semaglutide retained about 80%. The study also noted that the pill helped maintain improvements in blood pressure, cholesterol, and blood sugar levels. Dr. Louis Aronne from Weill Cornell Medicine emphasized the potential of treating obesity as a chronic disease, which could reduce the need for multiple medications addressing related health issues. 
